Phillips FM, Coric D, Sasso R, et al. - A prospective, multicenter, concurrently- and historically-controlled, FDA-approved investigational device exemption (IDE) clinical trial was designed to assess the safety and efficacy of the novel M6-C compressible artificial cervical disc in comparison with anterior cervical discectomy and fusion (ACDF) for individuals with single-level degenerative cervical radiculopathy. Researchers compared 160 M6-C individuals to a matched subset of 189 ACDF controls (46 concurrent and 143 historical controls) applying propensity score subclassification to control for selection bias. For the treatment of degenerative cervical radiculopathy, M6-C treatment demonstrated both safety and effectiveness. Treatment with M6-C indicated non-inferiority for the primary endpoint, displaying a similar ability to achieve Composite Clinical Success at 24 months. Nevertheless, for the secondary endpoints, M6-C individuals highlighted significantly improved pain and function in comparison with ACDF individuals, while maintaining range of motion, improving quality of life, and reducing analgesic and opioid usage at 2 years postoperatively relative to baseline.